TOVX Theriva Biologics (TOVX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000894158
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
11
13F, latest reported quarter
Theriva Biologics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Theriva Biologics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 6, 2023.
- -20.0% median (-10.7% mean) 90-day return after 6 previous buys.
- The trade is 5.6% of the 250,000 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO SHALLCROSS STEVEN A bought about $9.7K of TOVX on Jun 7, 2023; 11 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Feb 10, 2023.
- -19.8% median (-8.8% mean) 90-day return after 5 previous buys.
- The trade is 11.0% of the 236,000 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO SHALLCROSS STEVEN A bought about $16.4K of TOVX on Jun 6, 2023; 11 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Feb 2, 2023.
- -13.2% median (-2.6% mean) 90-day return after 4 previous buys.
- The trade is 11.9% of the 210,000 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO SHALLCROSS STEVEN A bought about $26.0K of TOVX on Feb 10, 2023; 11 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jan 25, 2023.
- -6.6% median (+7.2% mean) 90-day return after 3 previous buys.
- The trade is 13.5% of the 185,000 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO SHALLCROSS STEVEN A bought about $23.5K of TOVX on Feb 2, 2023; 11 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jan 20, 2023.
- +20.6% median (+20.6% mean) 90-day return after 2 previous buys.
- The trade is 15.6% of the 160,000 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO SHALLCROSS STEVEN A bought about $21.8K of TOVX on Jan 25, 2023; 11 funds added in the latest 13F quarter.7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
11 funds bought in last quarter
below 80% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-1072.3% net margin (latest quarter)
below 86% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
4.1% of the float short (float per yahoo 2026-10-27) · 3.3 days to cover · settled 2026-10-15
below 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TOVX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-44.1%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TOVX: institutional holders (13F)
13F holdings, latest reported quarter
486,179 sh
$121.5K
331,922 sh
$83.0K
294,021 sh
$73.6K
241,780 sh
$60.4K
112,076 sh
$28.0K
Congress trades in TOVX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TOVX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TOVX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$80.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$121.6K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$7.4K position · as of 2026-05-31
0.0%
Blackstone Alternative Multi-Strategy Fund
$8 position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 11 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TOVX financials
Net margin
-1072.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM TOVX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $0 |
| Mar 2026 | $300.0K |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM TOVX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | -681.3% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM TOVX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$19.2M |
| FY Dec 2022 | -$19.2M |
| FY Dec 2021 | -$12.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$2.9M |
| Sep 2025 | -$4.3M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$4.7M |
| Sep 2024 | -$3.9M |
At each fiscal year end
Single quarter
Debt to equity
0.14x
long-term 2025-12-31 (6 months older than the period end) plus current 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity TOVX
| FY Dec 2025 | 0.11x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.01x |
| FY Dec 2022 | 0.01x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.14x |
| Mar 2026 | 0.11x |
| Dec 2025 | 0.11x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.01x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-7.35x
TTM operating cash flow over long-term 2025-12-31 (6 months older than the period end) plus current 2023-12-31 (30 months older than the period end)
Cash flow to debt TOVX
| FY Dec 2025 | -9.61x |
| FY Dec 2024 | -109.27x |
| FY Dec 2023 | -84.43x |
| FY Dec 2022 | -68.64x |
| FY Dec 2021 | n/a |
| Jun 2026 | -7.35x |
| Mar 2026 | -8.29x |
| Dec 2025 | -9.61x |
| Sep 2025 | -119.21x |
| Jun 2025 | -116.59x |
| Mar 2025 | -108.46x |
| Dec 2024 | -109.27x |
| Sep 2024 | -83.50x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-101.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TOVX
| FY Dec 2025 | -137.8% |
| FY Dec 2024 | -91.6% |
| FY Dec 2023 | -41.3% |
| FY Dec 2022 | -33.6% |
| FY Dec 2021 | -47.1% |
| Jun 2026 | -101.9% |
| Mar 2026 | -138.9% |
| Dec 2025 | -137.8% |
| Sep 2025 | -167.0% |
| Jun 2025 | -161.8% |
| Mar 2025 | -105.8% |
| Dec 2024 | -91.6% |
| Sep 2024 | -81.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-32.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TOVX
| FY Dec 2025 | -64.5% |
| FY Dec 2024 | -56.6% |
| FY Dec 2023 | -28.9% |
| FY Dec 2022 | -27.7% |
| FY Dec 2021 | -36.2% |
| Jun 2026 | -32.9% |
| Mar 2026 | -61.0% |
| Dec 2025 | -64.5% |
| Sep 2025 | -73.8% |
| Jun 2025 | -75.6% |
| Mar 2025 | -61.3% |
| Dec 2024 | -56.6% |
| Sep 2024 | -52.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital TOVX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-51.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TOVX
| FY Dec 2025 | -85.9% |
| FY Dec 2024 | -69.1% |
| FY Dec 2023 | -37.8% |
| FY Dec 2022 | -32.8% |
| FY Dec 2021 | -39.5% |
| Jun 2026 | -51.6% |
| Mar 2026 | -83.7% |
| Dec 2025 | -85.9% |
| Sep 2025 | -101.0% |
| Jun 2025 | -101.8% |
| Mar 2025 | -76.0% |
| Dec 2024 | -69.1% |
| Sep 2024 | -65.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
0.26x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing TOVX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.34x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.27x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$883.4K
market value at close 2026-10-27 on 2026-08-07 shares, plus long-term 2025-12-31 (6 months older than the period end) plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value TOVX
| FY Dec 2025 | -$4.2M |
| FY Dec 2024 | -$6.6M |
| FY Dec 2023 | $160.3M |
| FY Dec 2022 | $136.7M |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.9M |
| Mar 2026 | -$3.5M |
| Dec 2025 | -$4.2M |
| Sep 2025 | -$3.4M |
| Jun 2025 | -$8.4M |
| Mar 2025 | -$6.8M |
| Dec 2024 | -$6.6M |
| Sep 2024 | $18.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield TOVX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -10.5% |
| FY Dec 2022 | -10.8% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing TOVX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$24.1M | -$26.3M | -$21.4M | -$21.6M |
| Net income | -$23.7M | -$25.7M | -$18.3M | -$19.7M |
| EPS (diluted) | -2.08 | -19.03 | -28.48 | -1.31 |
| Operating cash flow | -$16.7M | -$16.9M | -$19.0M | -$19.1M |
| Cash | $13.1M | $11.6M | $23.2M | $41.8M |
| Long-term debt | $1.7M | $92.0K | $162.0K | $221.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
TOVX Stock Sonar score 4/7 axes
Find similar shapesCompareTOVX ranks highest on profitability (46th percentile) and risk and compliance (42nd), and lowest on institutional and government (20th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
